Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Cost of Revenue (2018 - 2025)

BioNexus Gene Lab's Cost of Revenue history spans 8 years, with the latest figure at $551569.0 for Q3 2025.

  • For Q3 2025, Cost of Revenue fell 76.06% year-over-year to $551569.0; the TTM value through Sep 2025 reached $261562.0, up 55.17%, while the annual FY2024 figure was $2.0 million, 240.23% up from the prior year.
  • Cost of Revenue for Q3 2025 was $551569.0 at BioNexus Gene Lab, down from $1.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $3.5 million in Q2 2024 and bottomed at -$5.8 million in Q4 2023.
  • The 5-year median for Cost of Revenue is $2.2 million (2022), against an average of $1.5 million.
  • The largest annual shift saw Cost of Revenue crashed 333.48% in 2023 before it surged 1065.64% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $2.7 million in 2021, then dropped by 8.67% to $2.5 million in 2022, then plummeted by 333.48% to -$5.8 million in 2023, then surged by 31.9% to -$4.0 million in 2024, then soared by 113.87% to $551569.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Cost of Revenue are $551569.0 (Q3 2025), $1.9 million (Q2 2025), and $1.8 million (Q1 2025).